Shanghai INT Medical issues supplemental disclosure on sellers behind target equity acquisition

• Shanghai INT Medical Instruments issued a supplemental clarification on its discloseable acquisition of equity in a structural heart device target.
• Disclosure expanded on seller identities, beneficial owners, and fund-control chains; sellers described as independent third parties.
• Transaction terms reiterated: 3,613,909 shares for US$172.88 million, spanning ordinary, Series A preferred, Series B preferred shares.
• Share adjustment plan restated: issue additional Series B shares at nil consideration; align Series B effective price with Series A.
• Post-adjustment stake expected to exceed 30%; combined with further ordinary-share purchases, control of the target is targeted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Int Medical Instruments Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12330321), on September 11, 2026, and is solely responsible for the information contained therein.